trientine has been researched along with Ovarian Neoplasms in 3 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, DP | 1 |
| Chin-Sinex, H | 1 |
| Nie, B | 1 |
| Mendonca, MS | 1 |
| Wang, M | 1 |
| Fu, S | 1 |
| Naing, A | 1 |
| Fu, C | 1 |
| Kuo, MT | 1 |
| Kurzrock, R | 1 |
| Yellepeddi, VK | 1 |
| Vangara, KK | 1 |
| Kumar, A | 1 |
| Palakurthi, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Trientine and Carboplatin in Patients With Advanced Malignancies[NCT01178112] | Phase 1 | 56 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for trientine and Ovarian Neoplasms
| Article | Year |
|---|---|
Overcoming platinum resistance through the use of a copper-lowering agent.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cation Transport Proteins; | 2012 |
2 other studies available for trientine and Ovarian Neoplasms
| Article | Year |
|---|---|
Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer.
Topics: Antineoplastic Agents; Apoptosis; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Chelating | 2009 |
Comparative evaluation of small-molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Cell Line, Tumor; C | 2012 |